Indication
Acute Promyelocytic Leukemia
7 clinical trials
15 products
1 drug
Product
SY-2101Clinical trial
An Open-label Phase 1 Study to Evaluate Pharmacokinetics, Safety, and Tolerability of SY-2101 in Adult Patients With Acute Promyelocytic LeukemiaStatus: , Estimated PCD: 2024-01-03
Product
Arsenic TrioxideClinical trial
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic AcidStatus: Active (not recruiting), Estimated PCD: 2020-10-31
Drug
Arsenic TrioxideProduct
CytarabineProduct
DexamethasoneProduct
IdarubicinProduct
MitoxantroneProduct
TretinoinClinical trial
A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Product
Arsenic trioxideProduct
MercaptopurineProduct
MethotrexateClinical trial
Treatment Study for Children and Adolescents With Acute Promyelocytic LeukemiaStatus: Recruiting, Estimated PCD: 2025-10-09
Product
MylotargProduct
All-trans retinoic acidClinical trial
Multi-center Phase II Prospective Study for the Treatment of Chidamide and Venetoclax in Patients With All-trans Retinoic Acid (ATRA) and Arsenic (As) Resistant Acute Promyelocytic Leukemia (APL)Status: Recruiting, Estimated PCD: 2025-01-01
Product
Chidamide+venetoclaxClinical trial
Frontline Oral Arsenic Trioxide-based Induction in Newly Diagnosed Acute Promyelocytic LeukaemiaStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Optimum Induction Therapy of Low-risk Acute Promyelocytic Leukemia With All Oral DrugsStatus: Recruiting, Estimated PCD: 2024-12-31
Product
EtoposideProduct
Daunorubicin